Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Jan / Cracking Colon Cancer
Oncology Oncology Digital and computational pathology Technology and innovation

Cracking Colon Cancer

How a new clinically approved AI-based tool enables rapid microsatellite instability detection

By Georgia Hulme 01/25/2024 News 1 min read

Share

Microsatellite instability (MSI) – a tumor genotype characterized by mismatch errors of repetitive DNA – is found in 15 percent of colorectal cancer (CRC) patients and plays an important role in diagnostic, prognostic, and therapeutic outcomes. MSI also acts as a key biomarker for Lynch Syndrome – the most common cause of hereditary CRC. Universal screening of CRC patients for MSI is highly recommended, so a team of researchers from biotech company Owkin has recently developed MSIntuit – an artificial intelligence (AI)-based pre-screening tool for rapid MSI detection from H&E stained slides (1).

“Conventionally, MSI is diagnosed with immunohistochemistry or polymerase chain reaction,” says Charlie Saillard, lead data scientist at Owkin. “These tests contribute to an ever-increasing workload for pathologists and technicians.” In the study, researchers trained MSIntuit on samples from the Cancer Genome Atlas. A blind validation was then performed on an independent dataset of 600 consecutive CRC patients. The AI model either outputs “MSS-AI” (no further testing needed) or “undetermined,” where a standard MSI test is then required.

MSIntuit yielded a sensitivity of 96 percent and a specificity of 46 percent – rivaling the sensitivity of gold standard techniques and ruling out almost half of the non-MSI population. “Given the global shortage of pathologists worldwide, early rule-out of non-MSI patients can reduce the workload of pathologists and accelerate MSI screening in clinical practice,” says Saillard.

“This multidisciplinary approach is key to better understand the needs of pathologists and build a relevant tool that can help them in their daily practice,” says Saillard. He hopes the new AI-based tool will lead the way for other AI platforms to be deployed in clinical practice to help pathologists identify actionable biomarkers from routine histology slides. Saillard also believes that MSI pre-screening tools for other tumor types will be developed in the near future.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. C Saillard et al., Nat Commun, 14 (2023). PMID: 37932267

About the Author(s)

Georgia Hulme

Associate Editor for the Pathologist

More Articles by Georgia Hulme

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.